Massive transfusion associated with a hemolytic transfusion reaction: necessary precautions for prevention-Reference-Cited by-同舟云学术

Massive transfusion associated with a hemolytic transfusion reaction: necessary precautions for prevention

Published:2019-06-26 Issue:8 Volume:59 Page:2532-2535
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Davis Christopher S.¹^ORCID,Milia David¹,Gottschall Jerome L.²,Weigelt John A.¹

Affiliation:

1. Department of Surgery, Division of Trauma/Acute Care Surgery Medical College of Wisconsin Milwaukee Wisconsin

2. Department of Pathology Medical College of Wisconsin Milwaukee Wisconsin

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.15405

Reference6 articles.

1. Fatalities reported to FDA following blood collection and transfusion. Annual summary for fiscal year 2016 [Internet]. Silver Spring (MD): Food and Drug Administration Center for Biologics Evaluation and Research; 2016 [cited 2018 Jun 21]. Available from:https://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM598243.pdf.

2. Fatalities reported to FDA following blood collection and transfusion. Annual summary for fiscal year 2012 [Internet]. Silver Spring (MD): Food and Drug Administration Center for Biologics Evaluation and Research; 2012 [cited 2018 Jun 21]. Available from:http://wayback.archive-it.org/7993/20171114162543/https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm346639.htm.

3. Fatalities reported to FDA following blood collection and transfusion. Annual summary for fiscal year 2013 [Internet]. Silver Spring (MD): Food and Drug Administration Center for Biologics Evaluation and Research; 2013 [cited 2018 Jun 21]. Available from:http://wayback.archive‐it.org/7993/20171115110739/https://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM393080.pdf.

4. Fatalities reported to FDA following blood collection and transfusion. Annual summary for fiscal year 2014 [Internet]. Silver Spring (MD): Food and Drug Administration Center for Biologics Evaluation and Research; 2014 [cited 2018 Jun 21]. Available from:http://wayback.archive-it.org/7993/20171114162535/https://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM459461.pdf.

5. Fatalities reported to FDA following blood collection and transfusion. Annual summary for fiscal year 2015 [Internet]. Silver Spring (MD): Food and Drug Administration Center for Biologics Evaluation and Research; 2015 [cited 2018 Jun 21]. Available from:http://wayback.archive-it.org/7993/20171114162532/https://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM518148.pdf.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative evaluation of titer estimation of ABO isoagglutinins using three different methods;Indian Journal of Transplantation;2023

2. A prospective observational study to compare abo isoagglutinin titer by conventional test tube and column agglutination technique after heat inactivation of plasma in O blood group individuals;Indian Journal of Transplantation;2023

3. Comparative assessment of dithiothreitol‐treated ABO isoagglutinin titres performed by two methods;ISBT Science Series;2021-11

4. Patterns of paediatric massive blood transfusion protocol use in trauma and non‐trauma patients;Transfusion Medicine;2021-10-27

5. A prospective, observational study to compare effect of DTT treatment and heat inactivation on ABO isoagglutinin titers in O blood group donors;ISBT Science Series;2021-05-06